Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U9LT
|
|||
| Former ID |
DIB016819
|
|||
| Drug Name |
Y-39983
|
|||
| Synonyms |
RKI-983; SNJ-1656; ROCK inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis; Rho-associated protein kinase inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Phase 1/2 | [1] | |
| Company |
Mitsubishi Pharma Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H16N4O
|
|||
| Canonical SMILES |
CC(C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2)N
|
|||
| InChI |
1S/C16H16N4O/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15/h2-10H,17H2,1H3,(H2,18,19,20,21)/t10-/m1/s1
|
|||
| InChIKey |
JTVBXQAYBIJXRP-SNVBAGLBSA-N
|
|||
| CAS Number |
CAS 199433-58-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:91412
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Rho-associated protein kinase (ROCK) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00846989) Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension. U.S. National Institutes of Health. | |||
| REF 2 | Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.